Department of Gastroenterology, Maasstad Hospital, Rotterdam, the Netherlands.
Department of Internal Medicine, Erasmus University Medical Centre, Rotterdam the Netherlands.
Gastrointest Endosc. 2024 Jun;99(6):895-911.e13. doi: 10.1016/j.gie.2024.02.003. Epub 2024 Feb 13.
Obtaining adequate tissue samples in subepithelial lesions (SELs) remains challenging. Several biopsy techniques are available, but a systematic review including all available techniques to obtain a histologic diagnosis of SEL is lacking. The aim of this study was to evaluate the diagnostic yield and adverse event rates of endoscopic biopsies, EUS-guided FNA (EUS-FNA), EUS-guided fine-needle biopsy (FNB) (EUS-FNB), and mucosal incision-assisted biopsy (MIAB) for SELs in the upper GI tract.
A search strategy in multiple databases was performed. The primary outcome was diagnostic yield, defined as the percentage of procedures in which histology was obtained and resulted in a definitive histopathologic diagnosis. Secondary outcome measures included reported procedure-related adverse events, which were graded according to the AGREE (Adverse Events in Gastrointestinal Endoscopy) classification.
A total of 94 original articles were included. Studies were classified per endoscopic technique to obtain histopathology. This resulted in 8 included studies for endoscopic biopsy methods, 55 studies for EUS-FNA, 33 studies for EUS-FNB, and 26 studies for MIAB. Pooled rates for diagnostic yield were 40.6% (95% confidence interval [CI], 30.8-51.2) for endoscopic biopsy, 74.6% (95% CI, 69.9-78.7) for EUS-FNA, 84.2% (95% CI, 80.7-87.2) for EUS-FNB, and 88.2% (95% CI, 84.7-91.1) for MIAB. Reported procedure-related adverse events graded AGREE II or higher were 2.8% to 3.9% for endoscopic biopsies, 1.0% to 4.5% for EUS-FNA, .9% to 7.7% for EUS-FNB, and 1.9% to 7.9% for MIAB.
Based on the available evidence, MIAB and EUS-FNB seem to be most effective in terms of achieving a high diagnostic yield, with similar rates of adverse events.
在黏膜下病变(SEL)中获取足够的组织样本仍然具有挑战性。有几种活检技术可用,但缺乏包括所有可用技术以获得 SEL 组织学诊断的系统评价。本研究的目的是评估内镜活检、超声内镜引导下细针抽吸活检(EUS-FNA)、超声内镜引导下细针活检(EUS-FNB)和黏膜切开辅助活检(MIAB)在治疗上消化道 SEL 中的诊断率和不良事件发生率。
在多个数据库中进行了搜索策略。主要结局是诊断率,定义为获得组织学且病理诊断明确的操作比例。次要结局指标包括报告的与操作相关的不良事件,根据 AGREE(胃肠道内镜不良事件)分类进行分级。
共纳入 94 篇原始文章。根据获得组织病理学的内镜技术对研究进行分类。这导致 8 项内镜活检方法的研究、55 项 EUS-FNA 研究、33 项 EUS-FNB 研究和 26 项 MIAB 研究被纳入。内镜活检的诊断率为 40.6%(95%置信区间[CI],30.8-51.2),EUS-FNA 的诊断率为 74.6%(95% CI,69.9-78.7),EUS-FNB 的诊断率为 84.2%(95% CI,80.7-87.2),MIAB 的诊断率为 88.2%(95% CI,84.7-91.1)。报告的与操作相关的不良事件根据 AGREE II 或更高分级为 2.8%至 3.9%的内镜活检、1.0%至 4.5%的 EUS-FNA、0.9%至 7.7%的 EUS-FNB 和 1.9%至 7.9%的 MIAB。
根据现有证据,MIAB 和 EUS-FNB 在获得高诊断率方面似乎最有效,不良事件发生率相似。